MAPK8 and idiopathic pulmonary fibrosis: While various JNK inhibitors are postulated to exert anti-fibrotic effects in animal models by inhibiting macrophage polarization [124, 125], a phase II clinical trial utilizing the JNK inhibitor CC-930 for the treatment of patients with IPF was discontinued due to the occurrence of acute liver injury [126].